[ Sebacia raises $20M in Series D ]

Sebacia has raised $20 million in Series D funding.

Founded in 2010, Sebacia  is a clinical-stage private medical device company engaged in developing therapies for the treatment of dermatology diseases.

Sebacia intends to use the proceeds from the financing to complete a U.S. pivotal trial with expected results reporting by mid-2018, with submission and FDA response expected by the end of 2018. Further, with CE mark and market clearance for commercialization in Europe, Sebacia also intends to expand its commercial presence in the European Union. Additionally, the company plans to expand its worldwide patent estate, which includes the seminal selective photothermalysis methods developed by Dr. R. Rox Anderson at Massachusetts General Hospital.

Funding  Series D
Founded  2010
Country  USA
City  Duluth, Georgia
Founder / CEO  Anthony Lando
Deal Size  $20M
Investors  Salem Partners
 Partners Innovation Fund
 Accuitive Medical Ventures
 Domain Associates
 Versant Ventures
Previous Investors  Square 1 Bank
 Hercules Capital, Inc.
 Accuitive Medical Ventures
 Partners Innovation Fund
 Versant Ventures
 Domain Associates